VEC.L Share News (VEC)

ProStrakan non-executive director Dr Frank Fildes has acquired 40,000 shares in the pharma company at 70.11p each. The £28,000 investment takes his stake to 58,000 shares. The share price has fallen since the beginning of June because the US FDA has delayed a decision on Abstral, a treatment for pain in cancer patients. ProStrakan says that it remains on course for the launch of Abstral in the US in the second half of 2010.Shares in Vectura have come in for some profit-taking following their rise since Monday's full year figures. Standard Life has reduced its stake in the inhaled therapies developer by more than 1.1m shares, thereby taking its stake below 5%.Vectura reduced its loss before tax from £19.6m to £13.8m in the year to March 2010 thanks to higher licensing revenues. There was still £64.1m in the bank at the end of March 2010. FTSE TechMARK - RisersTriad Group (TRD) 25.00p +6.00%Torotrak (TRK) 19.00p +5.26%Cable & Wireless Worldwide (CW.) 87.85p +3.35%DRS Data (DRS) 15.50p +3.23%AEA Technology (AAT) 18.00p +2.86%Vernalis (VER) 36.50p +2.82%BT Group (BT.A) 134.90p +2.35%BATM Advanced (BVC) 24.50p +2.08%Oxford Biomedica (OXB) 9.75p +1.56%ProStrakan (PSK) 70.00p +1.45%FTSE TechMARK - FallersRM Group (RM.) 168.25p -5.87%Phytopharm (PYM) 8.75p -5.71%Psion (PON) 75.50p -5.63%Skyepharma (SKP) 34.00p -4.23%KCOM Group (KCOM) 51.25p -1.44%Vectura Group (VEC) 41.50p -1.19%Antisoma (ASM) 6.05p -1.14%Sepura (SEPU) 50.50p -0.98%Alphameric (ALM) 26.75p -0.93%Xaar (XAR) 115.25p -0.65%